---
title: "Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York | NKTR Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287827653.md"
description: "Nektar Therapeutics (Nasdaq: NKTR) will webcast its participation in the 2026 Jefferies Global Healthcare Conference in New York from June 2-4, 2026. The fireside chat is scheduled for June 3 at 1:20 p.m. ET, with a replay available for 30 days. Nektar focuses on developing treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate being rezpegaldesleukin (REZPEG)."
datetime: "2026-05-27T14:15:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287827653.md)
  - [en](https://longbridge.com/en/news/287827653.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287827653.md)
---

# Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York | NKTR Stock News

, /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York.

-   2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m. Eastern Time – webcast link here

The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the fireside chat will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective representative.

**About Nektar Therapeutics**

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

**Contacts**

**For Investors:**

Vivian Wu  
628-895-0661  
VWu@nektar.com

Corey Davis, Ph.D.  
LifeSci Advisors  
212-915-2577  
cdavis@lifesciadvisors.com

**For Media:**

Susan Roberts  
LifeSci Communications  
202-779-0929  
sroberts@lifescicomms.com

SOURCE Nektar Therapeutics

### Related Stocks

- [NKTR.US](https://longbridge.com/en/quote/NKTR.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [Is Nektar (NKTR) Betting Its Immunology Future on Rezpegaldesleukin’s Ambitious ZENITH-AD Phase 3 Program?](https://longbridge.com/en/news/289087155.md)
- [Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets | NKTR Stock News](https://longbridge.com/en/news/284455709.md)
- [BUZZ-Nektar starts $250 mln stock offering after alopecia treatment trial](https://longbridge.com/en/news/283401794.md)
- [Nektar Therapeutics Q4 2025 earnings preview](https://longbridge.com/en/news/278783039.md)
- [Nektar Therapeutics Launches $150 Million ATM Equity Program With Guggenheim and H.C. Wainwright](https://longbridge.com/en/news/285777430.md)